Business
Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A
--News Direct--Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive soon after announcing final results
About this update from Incannex Healthcare Inc.
[{"type":"text","content":"--News Direct--Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive soon after announcing final results for a Phase 1 clinical trial to assess pharmacokinetics and the safety of the company’s anti-inflammatory drug candidate IHL-675A. IHL-675A is a combination cannabinoid drug comprising cannabidiol (CBD) and hydroxychloroquine (HCQ) in a fixed dose combination.Contact DetailsProactive InvestorsJonathan Jackson+61 413 713 [email protected] source version on newsdirect.com: https://newsdirect.com/news/incannex-readying-for-phase-2-clinical-trial-of-anti-inflammatory-drug-ihl-675a-480207835","length":1194,"tagName":"div"}]